Status:
TERMINATED
Coagulation and Fibrinolysis of Estradiol in Transwomen
Lead Sponsor:
Medical College of Wisconsin
Conditions:
Transgenderism
Clotting Disorder
Eligibility:
MALE
18+ years
Phase:
EARLY_PHASE1
Brief Summary
The specific aim for our study is to measure coagulation system activation and fibrinolysis following transdermal versus sublingual versus oral estradiol versus in transgender women. Hypothesis: Tran...
Detailed Description
Subjects will report to our Adult Translational Research Unit for labs at baseline (2 weeks after HRT washout if needed). Both fibrinolysis and testosterone labs have a diurnal variation. Therefore, f...
Eligibility Criteria
Inclusion
- 18 years or older
- Gender identity of male to female or transwoman
Exclusion
- Liver disease
- History of blood clot
- Bleeding disorder
- Active or recent (e.g., within the past year) stroke
- Myocardial infarction,
- History of orchiectomy
- History of breast cancer,
- Known sensitivity or allergy to any components of the medications used
- Currently taking a potent CYP3A4 inhibitor or inducer.
Key Trial Info
Start Date :
December 7 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 23 2022
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT05387577
Start Date
December 7 2021
End Date
November 23 2022
Last Update
December 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Froedtert Hospital
Milwaukee, Wisconsin, United States, 53226